Travere Therapeutics, Inc. (TVTX)
| Market Cap | 1.55B |
| Revenue (ttm) | 204.15M |
| Net Income (ttm) | -237.05M |
| Shares Out | 60.57M |
| EPS (ttm) | -4.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 537,626 |
| Open | 25.11 |
| Previous Close | 25.23 |
| Day's Range | 24.76 - 26.73 |
| 52-Week Range | 12.75 - 33.09 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 32.71 (+24.5%) |
| Est. Earnings Date | Oct 28, 2021 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thio...
Financial Performance
In 2020, TVTX's revenue was $198.32 million, an increase of 13.11% compared to the previous year's $175.34 million. Losses were -$169.43 million, 15.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price forecast is 32.71, which is an increase of 24.47% from the latest price.
News
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics to Report Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close o...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement e...
Travere Therapeutics Announces Transition of Chief Medical Officer
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons...
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe,...
ST. GALLEN, Switzerland & SAN DIEGO, Calif.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced...
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe,...
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
Ms. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board Ms. Williams-Brinkley brings more than 35 years of executive leadership experience i...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2021, the Compensation Committee of its Board of Directors granted inducemen...
See Why Travere Therapeutics Stock Moving Higher On Tuesday
Travere Therapeutics Inc (NASDAQ: TVTX) has concluded a Type A meeting with the FDA related to sparsentan in focal segmental glomerulosclerosis (FSGS). See: Travere Therapeutics' Sparsentan Program S...
Travere (TVTX) Announces Data on Rare Kidney Disease Drug
Travere (TVTX) announces positive interim data from the ongoing study of its investigational candidate, sparsentan, for the treatment of IgAN, a rare kidney disorder. Resultantly, the stock rises
Here's Why Travere Therapeutics Stock Is Climbing Today
Investors are cheering positive phase 3 trial results with sparsentan that suggest it could become an important new treatment for a rare kidney disease.
TVTX Stock: Why Travere Therapeutics Stock Is Rocketing Higher Today
Travere Therapeutics (TVTX) stock is on the rise Monda and it's all thanks to positive interim results from one of its clinical trials. The post TVTX Stock: Why Travere Therapeutics Stock Is Rocketing H...
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate
Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of...
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere (TVTX) delivered earnings and revenue surprises of 12.33% and 8.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics: Q2 Earnings Insights
Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over the past year to ($0.39),...
Travere Therapeutics Reports Second Quarter 2021 Financial Results
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021
Earnings Preview: Travere Therapeutics (TVTX) Q2 Earnings Expected to Decline
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere Therapeutics to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of ...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2021, the Compensation Committee of its Board of Directors granted inducement equi...
New Strong Sell Stocks for June 25th
CVGW, KDNY, CMTL, GPL and TVTX have been added to the Zacks Rank #5 (Strong Sell) List on June 25, 2021.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investo...
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in June:
Why Travere Therapeutics Stock Is Plummeting Today
The FDA quashes the company's hopes for accelerated approval of a key pipeline drug.
Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data
Following the pre-NDA meeting, the FDA has asked Travere Therapeutics Inc (NASDAQ: TVTX) to submit additional data for the sparsentan program in focal segmental glomerulosclerosis (FSGS), characterized ...
Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis
Conference call and webcast to be held at 4:30p.m. ET Conference call and webcast to be held at 4:30p.m. ET